Abstract

The infection with coronavirus disease - 2019 (COVID-19) is a double risk for patients with diabetes. Diabetes has been stated to be a risk factor for the seriousness of the condition, whereas patients continue to regulate glucose in a situation of lower and more complex intake of food.

COVID-19 is caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), which has spread rapidly to many more than 160 countries worldwide [1,2]. The mechanism for transmitting the virus is mainly through the transfer of respiratory droplets between humans [1]. The average incubation period is 5 days, accompanied by symptomatic illness lasting 1 - 2 weeks [3]. It is characterized by a wide range of symptoms including coughing, fever, myalgia and breathing problems like viral pneumonia, and respiratory failure. In the worst cases, these can lead to death [4-6]. The average duration from first hospitalizations has been 6 - 7 days [7-9]. A percentage of those infected are either without symptoms (but still infective) or who have mild symptoms [10-12].

References

1. Yi Y., et al. “COVID-19: what has been learned and to be learned about the novel coronavirus disease”. International Journal of Biological Sciences 10 (2020): 1753‐1766.
2. Finelli C. “Obesity and Covid 19: Possible Risks!”. EC Endocrinology and Metabolic Research6 (2020): 1-3.
3. Lauer SA., et al. “The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application”. Annals of Internal Medicine 9 (2020): 577‐582.
4. Deng Y., et al. “Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study”. Chinese Medical Journal (2020).
5. Chen G., et al. “Clinical and immunological features of severe and moderate coronavirus disease 2019”. Journal of Clinical Investigation 5 (2020): 2620‐2629.
6. Chen T., et al. “Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study”. The British Medical Journal‎ 368 (2020): m1091.
7. Bhatraju PK., et al. “Covid-19 in Critically Ill Patients in the Seattle Region - Case Series”. The New England Journal of Medicine 21 (2020): 2012‐2022.
8. Liang WH., et al. “Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China”. European Respiratory Journal (2020): 2000562.
9. Liu W., et al. “Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease”. Chinese Medical Journal 9 (2020): 1032‐1038.
10. Noh JY., et al. “Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration (2020).
11. Park SW., et al. “The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak (2020): 100392.
12. Yan X., et al. “Duration of SARS-CoV-2 viral RNA in asymptomatic carriers”. Critical Care 1 (2020): 245.
13. Azziz-Baumgartner E., et al. “Mortality, severe acute respiratory infection, and influenza-like illness associated with influenza A (H1N1) pdm09 in Argentina, 2009”. PLoS One10 (2012): e47540.
14. Badawi A and Ryoo SG. “Prevalence of Diabetes in the 2009 Influenza A (H1N1) and the Middle East Respiratory Syndrome Coronavirus: A Systematic Review and Meta-Analysis”. Journal of Public Health Research 3 (2016): 733.
15. Kumar A., et al. “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis”. Diabetology and Metabolic Syndrome 4 (2020): 535‐545.
16. Zhou T., et al. “Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus”. Journal of Diabetes Research (2018): 7457269.
17. Morgan DJ., et al. “Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia”. Frontiers in Immunology 9 (2018): 2943.
18. Wu Y., et al. “Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention”. International Journal of Medical Sciences 11 (2014): 1185‐1200.
19. Al-Goblan AS., et al. “Mechanism linking diabetes mellitus and obesity”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7 (2014): 587‐591.
20. Honce R and Schultz-Cherry S. “Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution”. Frontiers in Immunology 10 (2019): 1071.
21. Finelli C. “Obesity and immunotherapy: the surprisingly positive association!”. Immunotherapy (2020).
22. Marillier M., et al. “Breathing at Extremes: The Restrictive Consequences of Super- and Super-Super Obesity in Men and Women”. Chest (2020).
23. Boukhris M., et al. “Cardiovascular implications of the COVID-19 pandemic: a global perspective”. Canadian Journal of Cardiology (2020).
24. Liu M., et al. “Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management”. Journal of Translational Internal Medicine 1 (2020): 9‐19.
25. Furuhashi M., et al. “Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19”. Hypertension Research (2020): 1‐4.
26. Javanmard SH., et al. “Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox”. Infection Control and Hospital Epidemiology (2020): 1‐2.
27. Hine JL., et al. “Association between glycaemic control and common infections in people with Type 2 diabetes: a cohort study”. Diabetic Medicine 4 (2017): 551‐557.